Next Article in Journal
Glucan–Resveratrol–Vitamin C Combination Offers Protection against Toxic Agents
Next Article in Special Issue
The Receptors that Mediate the Direct Lethality of Anthrax Toxin
Previous Article in Journal
Shiga Toxins and the Pathophysiology of Hemolytic Uremic Syndrome in Humans and Animals
Previous Article in Special Issue
Anthrax Lethal Toxin and the Induction of CD4 T Cell Immunity
Toxins 2012, 4(11), 1288-1300; doi:10.3390/toxins4111288

Pharmacophore Selection and Redesign of Non-nucleotide Inhibitors of Anthrax Edema Factor

1,2,3,4,* , 1
Received: 24 September 2012 / Revised: 25 October 2012 / Accepted: 1 November 2012 / Published: 8 November 2012
(This article belongs to the Special Issue Anthrax Toxin)
View Full-Text   |   Download PDF [667 KB, 28 November 2012; original version 8 November 2012]   |   Browse Figures


Antibiotic treatment may fail to protect individuals, if not started early enough, after infection with Bacillus anthracis, due to the continuing activity of toxins that the bacterium produces. Stable and easily stored inhibitors of the edema factor toxin (EF), an adenylyl cyclase, could save lives in the event of an outbreak, due to natural causes or a bioweapon attack. The toxin’s basic activity is to convert ATP to cAMP, and it is thus in principle a simple phosphatase, which means that many mammalian enzymes, including intracellular adenylcyclases, may have a similar activity. While nucleotide based inhibitors, similar to its natural substrate, ATP, were identified early, these compounds had low activity and specificity for EF. We used a combined structural and computational approach to choose small organic molecules in large, web-based compound libraries that would, based on docking scores, bind to residues within the substrate binding pocket of EF. A family of fluorenone-based inhibitors was identified that inhibited the release of cAMP from cells treated with EF. The lead inhibitor was also shown to inhibit the diarrhea caused by enterotoxigenic E. coli (ETEC) in a murine model, perhaps by serving as a quorum sensor. These inhibitors are now being tested for their ability to inhibit Anthrax infection in animal models and may have use against other pathogens that produce toxins similar to EF, such as Bordetella pertussis or Vibrio cholera.
Keywords: computational design; library screening; fluorenone; adenylyl cyclase toxin computational design; library screening; fluorenone; adenylyl cyclase toxin
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
MDPI and ACS Style

Schein, C.H.; Chen, D.; Ma, L.; Kanalas, J.J.; Gao, J.; Jimenez, M.E.; Sower, L.E.; Walter, M.A.; Gilbertson, S.R.; Peterson, J.W. Pharmacophore Selection and Redesign of Non-nucleotide Inhibitors of Anthrax Edema Factor. Toxins 2012, 4, 1288-1300.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


Cited By

[Return to top]
Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert